Immutrin raises $87M to advance drug for progressive heart disease
Source: BioPharma Dive - Latest News
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.